key: cord-0941817-xprqjlnq
authors: Chen, Qingquan; Yang, Xiuqiong; Fang, Yingying; Chen, Gongping; Lv, Xiaoting
title: Potential benefits of precise corticosteroid therapy for critical COVID-19
date: 2021-11-18
journal: Respir Physiol Neurobiol
DOI: 10.1016/j.resp.2021.103813
sha: d70915fa21fdfb5cf74c7ed041d503aca4124766
doc_id: 941817
cord_uid: xprqjlnq

This study was aimed to explore the precise dose of corticosteroid therapy in critical COVID-19. A total of forty-five critical COVID-19 patients were enrolled. The process of critical COVID-19 was divided into alveolitis and fibrosis stages. Most nonsurvivors died in fibrosis phase. Nonsurvivors had more dyspnea symptoms, fewer days of hospitalization, shorter duration of alveolitis and fibrosis. High-dose daily corticosteroid therapy (≥150 mg/d) was associated with shorter survival time and lower lymphocyte count in fibrosis phase. Moreover, a high cumulative dose (≥604 mg) was tied to longer duration of virus shedding, lower oxygenation index (OI), higher incidence of tracheal intubation, fewer lymphocytes and higher levels of C-reactive protein (CRP) and lactate dehydrogenase (LDH). In alveolitis phase, the low-to-moderate-dose daily corticosteroid therapy and a small cumulative dose reduced lymphocytes. In conclusion, low-to-moderate dose corticosteroids may be beneficial in the fibrosis phase. High-dose corticosteroid therapy in the fibrosis phase aggravates the severity of critical COVID-19.

. This finding was further supported by autopsy results of critical COVID-19 patients who died in 17-19 days and which exhibited significant proliferation of type II alveolar epithelia, organization of exudates in some alveolar cavities, and pulmonary interstitial fibrosis (Yao, et al., 2020) .

The underlying pathogenesis of severe influenza infection is characterized by overproduction of proinflammatory cytokines/chemokines and activated lymphocytes, leading to severe lung damage and delayed recovery (Louie, et al., 2009; Mauad, et al., 2010; Shieh, et al., 2010; Yang, et al., 2014; Yu, et al., 2011; Zhao, et al., 2012) .

Although corticosteroids were widely used in SARS, Middle East respiratory syndrome (MERS), and COVID-19 (Arabi, et al., 2018; Stockman, et al., 2006) , the indication and curative effects of corticosteroid therapy are still disputed. Corticosteroid treatment may potentially decrease mortality and ameliorate acute lung injury induced by influenza A (H1N1) pdm09 virus (Li, et al., 2012; Ottolini, et al., 2003) and it may be beneficial for COVID-19 patients who developed ARDS on disease progression . Yet insufficient evidence exists to recommend corticosteroid treatment for 2019-nCoV lung injury (Russell, et al., 2020) . Current interim guidance from the WHO on the clinical management of SARS-CoV-2 infection advises against the use of corticosteroids unless otherwise indicated (World Health Organization, 2020) , while the National Health Commission of the People's Republic of China has suggested that corticosteroid therapy could be used for progressive critical COVID-19 patients (National Health Commission of the People's Republic of China, 2020).

This study aimed to describe the clinical characteristics of critical COVID-19 patients and to explore the effects of different doses of adjuvant corticosteroid therapy in alveolitis and fibrosis stages according to the CT findings and its predictive value for clinical prognosis.

J o u r n a l P r e -p r o o f 2.1 Study design and participants All patients aged fourteen or over were enrolled in the ICU ward of the Third People's Hospital of Yichang City (one of the mostly epidemic areas in China) from January 27 to March 20, 2020. According to the WHO interim guidance (World Health Organization, 2020), a total of 45 patients were subsequently confirmed as critical COVID-19 cases and jointly diagnosed by a Multidisciplinary diagnosis and treatment (MDT) team composed of infectious disease experts, respiratory medicine staff, critical care medical staff, and emergency medicine staff. Critical cases were met with any one of the following: respiratory failure and required mechanical ventilation, the occurrence of shock, and combined failure of other organs that required ICU monitoring and treatment (National Health Commission of the People's Republic of China, 2020). Patients who had previously received chronic corticosteroid therapy had been excluded. All discharged survivors were detected with twice negative nucleic acid tests of throat swab samples (National Health Commission of the People's Republic of China, 2020).

Systemic corticosteroid therapy in the disease course was defined as any intended therapeutic use of corticosteroids, including methylprednisolone, and/or prednisolone via oral or intravenous routes, but excluding inhalational therapy.

Low-to-moderate-dose daily corticosteroids were defined as 25-150 mg.d -1 methylprednisolone or equivalent, while high-dose daily corticosteroids were defined as ≥150 mg.d -1 methylprednisolone or equivalent (Lamontagne, et al., 2010; Tagami, et al., 2015; Tang, et al., 2009) . No patients had received corticosteroid therapy at a certain dose range of 0-25 mg/d. Patients without corticosteroid treatment were classified as the corticosteroid-free group.

The cases were collected according to the methods of Xiao-Ting Lv et al. 2020 [31] .General information included age, gender, days from illness onset to hospital admission, history of living/traveling in the epidemic area, comorbidities such as J o u r n a l P r e -p r o o f chronic obstructive pulmonary disease (COPD), hypertension, coronary heart disease, cerebrovascular disease, diabetes, renal dysfunction, malignant tumors, administration of immunosuppressive agents and so on, clinical symptoms on admission (fever, cough, dyspnea, fatigue and others), duration of viral shedding, days of hospitalization, disease duration, duration of alveolitis and fibrosis phases, rate of shock, incidence of tracheal intubation, and time of tracheal intubation. Chest CT images were used to make a distinction between the alveolitis and fibrosis phases.

The hemolytic agents for blood cell analysis were detected by the detection Kit 

Statistical analysis was performed using the SPSS 18.0 software package (SPSS Inc., J o u r n a l P r e -p r o o f Chicago, IL, USA). Continuous variables were expressed as median (interquartile range, IQR) and compared by Mann-Whitney U test. Comparisons were made by 2  test for categorical variables. Survival data were analyzed by using Kaplan-Meier survival curves and log-rank (Mantel-Cox) test. For all tests, a two-sided P value<0.05 was considered statistically significant.

Patients were included and divided into nonsurvivors (n=17) and survivors (n=28) groups. Nonsurvivors had fewer days of hospitalization, a shorter duration of disease in both alveolitis and fibrosis stages, and more dyspnea symptoms than survivors (P=0.0003, 0.001, and 0.015, respectively). There was no significant difference between the two groups in age (P=0.806), gender (P=0.463), days from illness onset to hospital admission (P=0.564), duration of viral shedding (P=0.071), or history of living/traveling in Wuhan city (P=0.051) as well as complications. Compared with survivors, nonsurvivors had lower OI (P<0.0001), higher rates of shock (P<0.0001), increased incidence of tracheal intubation, and longer tracheal intubation time (P=0.0001 and 0.001, respectively) during hospitalization. Significantly elevated levels of LDH, CRP and DD, fewer lymphocytes as well as a greatly increased degree of LDH and CRP in the fibrosis stage was demonstrated in nonsurvivors compared survivors (Table 1) .

Chest CT imaging findings in our study confirmed that all critical patients had both alveolitis and fibrosis stages, consistent with the existing literature reports 5, 12 . Diffuse pulmonary infiltration was evident shown in the alveolitis stage, at which point period tracheal intubation and invasive mechanical ventilation were often performed as patients' condition deteriorated (Fig. 1A) . After a few days of treatment with different doses of corticosteroids, some patients were extubated as lesions of GGO exhibited J o u r n a l P r e -p r o o f reduced and slight range (Fig. 1B) . Only a small number of nonsurvivors failed to pass through the crisis of the alveolitis stage and died in the alveolitis stage (3/17).

The illness frequently progressed into the fibrosis stage, characterized by consolidation and obvious changes of diffuse interstitial fibrosis including signs of air bronchogram sign, bronchiectasis, and reticular pattern were shown on Chest CT (Fig.   1C ). Notably, most nonsurvivors died in the fibrosis phase (14/17). Due to a few days of treatment with corticosteroids in the fibrosis stage, interstitial fibrosis was absorbed gradually, and Chest CT in survivors exhibited a scanty amount of shadows of irregular linear or fibrotic reticular appearance accompanied by bronchiectasis ( Fig.   1D -F).

The cutoff point of the cumulative dose of corticosteroids administrated in the alveolitis phase for differentiating nonsurvivors from survivors was 180 mg, according to the receiver operating characteristic curve (ROC) analysis. Therefore, cases were divided into three groups based on cumulative dose of corticosteroids in the alveolitis phase: a corticosteroid-free group, a low-to-moderate dose group (less than 180 mg), and a high dose group (more than 180 mg). Our results showed that a high cumulative dose ( Fig. 2A) and a low-to-moderate daily dose of corticosteroid therapy ( Fig. 2B ) positively reduced the counts of peripheral lymphocytes.

The cutoff point for the cumulative dose of corticosteroids administrated in the fibrosis phase for differentiating nonsurvivors from survivors was 604 mg, according to the ROC analysis. Additionally, the cumulative doses of corticosteroids administrated in the fibrosis phase were divided into three groups: a corticosteroid-free group, a low-to-moderate group (less than 604 mg) and a high dose group (more than 604 mg). Compared with corticosteroid-free treatment and low-to-moderate dose corticosteroid therapy, high cumulative dose ( although there was no difference among these groups in the alveolitis phase (Fig. 2E ).

There was no difference in the duration of viral shedding between patients treated with different doses of corticosteroids in the alveolitis phase (Fig.3A) . However, in the fibrosis phase, a high cumulative dose of corticosteroid therapy (≥604 mg) was significantly associated with longer duration of virus shedding, lower OI, a higher incidence of tracheal intubation, and higher levels of CRP and LDH, when compared to corticosteroid-free and low-to-moderate dose of corticosteroid therapy (less than 604 mg) (Fig.3B , C, E, and G). Additionally, the rates of shock complications in patients treated with the high cumulative dose of corticosteroid were higher than the corticosteroid-free group, although there was no difference between high and low-to-moderate doses of corticosteroid therapy groups (Fig.3D) . Serum DD levels did not differ between groups (Fig.3H ).

Our results showed that comprising of 45 hospitalized critical COVID-19 patients, among whom 73.3% were older than 60 years. Most nonsurvivors of critical COVID-19 patients in the study died in the fibrosis phase (14/17) and had a shorter duration of alveolitis and fibrosis, more severe symptoms of dyspnea at its onset, lower OI, higher rate of shock, increased incidence of tracheal intubation and longer time of tracheal intubation. Our study also demonstrated elevated levels of LDH, CRP, and DD, fewer lymphocytes in the fibrosis stage in nonsurvivors than survivors, as well as an increased degree of LDH and CRP in the alveolitis and fibrosis stages of nonsurvivors. In addition, high-dose daily corticosteroid therapy (≥150 mg/d) was significantly associated with a shorter survival time and lower levels of peripheral J o u r n a l P r e -p r o o f lymphocytes in the fibrosis phase. High cumulative dose (≥604 mg) in the fibrosis phase was also associated with a longer duration of virus shedding, lower OI, higher incidence of tracheal intubation, higher incidences of shock, fewer lymphocytes and higher levels of CRP and LDH than corticosteroid-free and low cumulative dose group (<604 mg). In the alveolitis phase, even a low-to-moderate-dose daily corticosteroid therapy (25-150 mg/d) and a relatively small cumulative dose (≥180 mg)

can reduce the counts of lymphocytes, although different doses of corticosteroids yielded no difference in patient survival time.

Stratified analysis of critical COVID-19 patients with different stages was performed according to the Chest CT imaging findings of alveolitis and fibrosis stages. In the alveolitis phase, our results showed that even small-dose corticosteroid therapy could reduce the counts of lymphocytes, but there was no difference in survival time and duration of viral shedding between patients treated with different corticosteroids dose.

Only a small number of nonsurvivors failed to pass through the crisis of alveolitis stage and died in the alveolitis stage (3/17). Previous studies on ARDS revealed that low-to-moderate dose corticosteroids reduced mortality significantly, but high-dose (>2.0 mg·kg−1·d−1 methylprednisolone) daily corticosteroid therapy had no such benefit (Lamontagne, et al., 2010; Tang, et al., 2009 ). Although early corticosteroid treatment was associated with a higher subsequent plasma viral load in SARS (N. , corticosteroids could be used for COVID-19 patients with progressive deterioration of OI, rapid progress of imaging and short hyperactivation time of inflammatory reaction. Early treatment of corticosteroids may be an independent prognostic factor in patients with IPF-AE (Atsumi, et al., 2018) . A proper dose of corticosteroid therapy in the first 3-5 days could enhance oxygen saturation (SaO2) and arterial oxygen tension (PaO2)/inspiratory oxygen fraction (FiO2), and might not increase ICU mortality in critical COVID-19 patients, thus precise corticosteroid therapy may have potential benefits for critical COVID-19 in the alveolitis phase (National Health Commission of the People's Republic of China, 2020; . Severe COVID-19 cases showed elevated levels of J o u r n a l P r e -p r o o f proinflammatory cytokines (TNF-α, IL-1, and IL-6) and chemokines (IL-8) compared to mild cases, and pathological findings in COVID-19 patients showed pneumocytes desquamation, hyaline membrane formation, interstitial monocytes and lymphocytes inflammatory infiltrates, indicating acute respiratory distress syndrome , which were similar to the results in SARS and MERS (Min, et al., 2016; Wong, et al., 2004) . Cytokine storms made damaged tissues worse, leading to diffuse lung infiltration as showed on our Chest CT in the alveolitis stage. Low-to-moderate dose corticosteroids might have multiple effects on damaged tissues through inhibiting immune-related cytokines in the acute alveolitis phase, therefore low-to-moderate dose corticosteroids might help critical patients through the inflammation storm without delaying the clearance of SARS-CoV2 virus RNA in the alveolitis phase.

Our study showed that most nonsurvivors died in the fibrosis phase, indicating that this rapidly progressing fibrosis stage may be more dangerous than the alveolitis stage.

However, the critical COVID-19 patients did not benefit from the high-dose daily corticosteroid therapy (≥150 mg/d) or high integral dose (≥604 mg) in the fibrosis phase. A high cumulative dose (≥604 mg) in the fibrosis phase was also associated with a longer duration of virus shedding, lower OI, higher incidence of tracheal intubation, higher rates of shock complications, fewer lymphocytes and higher levels of CRP and LDH. High-dose corticosteroid therapy might exacerbate the development of critical COVID-19 in the fibrosis phase, resulting in increased mortality, although the harmful effects were not present in the low-to-moderate dose and corticosteroid-free groups.

In the fibrosis stage of critical COVID-19, there were many possible causes for the harmful effect of high-dose corticosteroids. On the one hand, our Chest CT in the fibrosis stage indicated that interstitial fibrosis caused by the disease might lead to respiratory failure. Studies have also that critical COVID-19 patients had lighter exudation of alveolar fluid and cellulose, less hyaline membrane, significantly altered proliferation of type II alveolar epithelial cells and bronchial mucosal epithelial cells, J o u r n a l P r e -p r o o f alveolar fleshy changes, and pathological interstitial fibrosis (Yao, et al., 2020) , indicating that the inflammation storm was ameliorated in the fibrosis stage, which would render high-dose corticosteroid therapy less effective than in the alveolitis phase. Thus, low-to-moderate-dose corticosteroid treatment may yield enough improvement of lung injury so as to reduce mortality in the fibrosis stage. On the other hand, our results showed that high-dose corticosteroid therapy delayed the clearance of SARS-CoV2 virus RNA in the fibrosis stage. Previous studies found that corticosteroid treatment delayed the clearance of viral RNA of MERS-CoV and SARS-CoV, increased complications including psychosis, diabetes, and avascular necrosis in SARS, and increased mortality of influenza (Arabi, et al., 2018; Li, et al., 2004; Ni, et al., 2019; World Health Organization, 2020; Xiao, et al., 2004) . In addition, lymphocytes, such as virus-specific CD4 and CD8 T cells, play a critical role in clearing the virus to provide partial protection and reduce symptoms, and the acute phase of SARS in humans is associated with a severe reduction in the number of T cells in the blood (Channappanavar, et al., 2014) . As most of the infiltrated lymphocytes in lung tissues were CD4-positive T cells, both helper T cells and suppressor T cells in peripheral blood were below normal levels, and a lower level of helper T cells was found in the severe group (Qin, et al., 2020) . Morbidity and mortality of SARS-CoV and MERS-CoV may be higher in the immunocompromised elderly than in younger adults (Peiris, et al., 2003; Perlman and Dandekar, 2005; Perlman and Netland, 2009; Talbot, 2017) . As humans age, there are progressive declines in the percentage of total lymphocytes, the absolute numbers of T and B cells, and the ratio of CD4 to CD8 T cells (Amadori, et al., 1995; Valiathan, et al., 2016) . Notably, a high proportion of critical COVID-19 patients in our study (73.3%) were older than 60 years, and high-dose corticosteroid therapy indeed induced lower levels of peripheral lymphocytes. The decreased lymphocytes in the fibrosis stage may be one reason for the delayed clearance of SARS-CoV2 virus RNA in high-dose corticosteroid therapy, followed by lower OI, higher incidence of tracheal intubation, a higher rate of shock complications and higher levels of CRP and LDH, which indicated the condition J o u r n a l P r e -p r o o f aggravation and significantly shorter survival time.

The progressive fibrosis stage of critical COVID-19 patients may be more dangerous than the alveolitis stage. According to the progression of the disease, low-to-moderate dose corticosteroids may be beneficial for critical COVID-19 patients in the fibrosis phase, while they should be used carefully in the alveolitis stage. High-dose corticosteroid therapy in the fibrosis phase aggravates the severity of critical COVID-19, resulting in increased mortality in the fibrosis phase.

We declare that we have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Chen GP, Chen QQ and Lv XT designed the research study and contributed the concept and definition of intellectual content; Fang YY and Yang XQ contributed literature search, clinical studies, experimental studies, data acquisition, data analysis and statistical analysis; Lv XT and Chen QQ contributed manuscript preparation, manuscript editing and manuscript review. All authors have read and approved the final manuscript. Lv XT, Chen GP, Chen QQ and Yang XQ contributed equally to this work and take responsibility for the integrity of the work as a whole from inception to published article. (n=17) Survivors (n=28) Age .001

Increase degree of DD (mg/L) ¶ -11.6(-32.8-0.5) 0.1(-2.2-4.1)

.026 †Thyroid dysfunction, prostatic hyperplasia, schizophrenia ‡Arthralgia, sputum, dizziness, nausea, chest pain, diarrhea §Time from illness onset to death or discharge, days ¶Difference between alveolitis and fibrosis stages

Genetic control of the CD4/CD8 T-cell ratio in humans

Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome

Prognostic Factors in the Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Retrospective Single-center Study

Emerging respiratory infections: The infectious disease pathology of SARS, MERS, pandemic influenza, and Legionella

T cell-mediated immune response to respiratory coronaviruses

New coronavirus infected pneumonia diagnosis and treatment plan (7th trial version)(National Health Office Medical Letter

The clinical pathology of severe acute respiratory syndrome (SARS): a report from China

Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR. Radiology

COVID-19: what is next for public health?

Use of Chest CT in Combination with Negative RT-PCR Assay for the

Corticosteroid therapy for acute lung injury, acute respiratory distress syndrome, and severe pneumonia: a meta-analysis of randomized controlled trials

Factors associated with psychosis among patients with severe acute respiratory syndrome: a case-control study

Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients

Corticosteroid treatment ameliorates acute lung injury induced by 2009 swine origin influenza A (H1N1) virus in mice

Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California

Lung pathology in a broad spectrum of disease severity

The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis

Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected

Combination anti-inflammatory and antiviral therapy of influenza in a cotton rat model

Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19)

The severe acute respiratory syndrome

Immunopathogenesis of coronavirus infections: implications for SARS

Coronaviruses post-SARS: update on replication and pathogenesis

Dysregulation of immune response in patients with COVID-19 in Wuhan, China

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States

SARS: systematic review of treatment effects

Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients

Influenza in Older Adults

Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study

Chest CT for Typical 2019-nCoV Pneumonia: Relationship to Negative RT-PCR Testing

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Influenza pneumonia among adolescents and adults: a concurrent comparison between influenza A (H1N1) pdm09 and A